This knowledge is now incorporated in the new diagnostic criteria for MCI, indicating that positive biomarkers of Aβ accumulation (e.g., CSF Aβ42) and neuronal injury (e.g., CSF T-tau and p-tau) confers the highest likelihood that AD pathophysiological processes are the cause of the cognitive dysfunction; and that individuals with this biomarker profile are more likely to decline or progress to dementia due to AD in relatively short periods (Albert et al., 2011). The gene discussed is MAPT; the disease is dementia.